11 studies found for:    CLN1
Show Display Options
Rank Status Study
1 Completed W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne
Condition: Acne Vulgaris
Intervention: Drug: Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,
2 Completed Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)
Condition: Neuronal Ceroid Lipofuscinosis
Interventions: Procedure: Surgery to implant human CNS stem cells (HuCNS-SC);   Drug: Medication to suppress the immune system
3 Completed Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis
Condition: Infantile Neronal Ceroid Lipofuscinosis
Intervention: Drug: Cystagon
4 Completed Effects of 2006-RD-05 on Salivary and Serum Immunoglobulin A (IgA) Levels in Healthy Subjects
Condition: Healthy
Interventions: Dietary Supplement: 2006-RD-05;   Dietary Supplement: Placebo
5 Recruiting Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
Condition: Cancer
Intervention: Drug: SNX-5422
6 Completed Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
Condition: Cancer
Intervention: Drug: SNX-5422
7 Recruiting Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
Condition: Cancer
Intervention: Drug: SNX-5422
8 Completed Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Condition: Cancer
Intervention: Drug: SNX-5422
9 Recruiting Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
Condition: Cancer
Intervention: Drug: SNX-5422
10 Completed Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Condition: Hematologic Neoplasms
Intervention: Drug: SNX-5422
11 Active, not recruiting Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Condition: Cancer
Intervention: Drug: SNX-5422

Indicates status has not been verified in more than two years